구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | UniCAR02-T (IMP) |
Overview Company | AvenCell Europe GmbH |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.. As an oral small-molecule drug that selectively inhibits ROCK2, Belm exhibits unique advantages in the treatment of hormone-dependent/refractory cGVHD. However, impurity control and stability during the production of its API remain … |
Clinical Safety signal | Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.. As an oral small-molecule drug that selectively inhibits ROCK2, Belm exhibits unique advantages in the treatment of hormone-dependent/refractory cGVHD. However, impurity control and stability during the production of its API remain … |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | UniCAR02-T (IMP) |
Overview Company | AvenCell Europe GmbH |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.. As an oral small-molecule drug that selectively inhibits ROCK2, Belm exhibits unique advantages in the treatment of hormone-dependent/refractory cGVHD. However, impurity control and stability during the production of its API remain … |
Clinical Safety signal | Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.. As an oral small-molecule drug that selectively inhibits ROCK2, Belm exhibits unique advantages in the treatment of hormone-dependent/refractory cGVHD. However, impurity control and stability during the production of its API remain … |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교